Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Cormorant Asset Management, LP (CIK 1583977) reported $1.99B across 42 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: PRAX ($285.3M, 14.33%), ($160.0M, 8.04%), EYPT ($106.5M, 5.35%), EWTX ($102.7M, 5.16%), ERAS ($93.8M, 4.71%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PRAX | PRAXIS PRECISION MEDICINES I | $285.3M | 14.33% | 885,500 | Trimmed |
| 2 | BRIDGEBIO ONCOLOGY THERAPEUT | $160.0M | 8.04% | 17.9M | Hold | |
| 3 | EYPT | EYEPOINT INC | $106.5M | 5.35% | 8.3M | Hold |
| 4 | EWTX | EDGEWISE THERAPEUTICS INC | $102.7M | 5.16% | 3.3M | Trimmed |
| 5 | ERAS | ERASCA INC | $93.8M | 4.71% | 5.8M | New |
| 6 | RAPP | RAPPORT THERAPEUTICS INC | $92.5M | 4.65% | 3.0M | Trimmed |
| 7 | ALMS | ALUMIS INC | $87.0M | 4.37% | 3.9M | Added |
| 8 | ABVX | ABIVAX SA | $84.6M | 4.25% | 760,000 | Trimmed |
| 9 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $83.5M | 4.19% | 4.5M | Added |
| 10 | DNTH | DIANTHUS THERAPEUTICS INC | $79.7M | 4.00% | 950,000 | New |
| 11 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $77.3M | 3.88% | 1.1M | Hold |
| 12 | OLMA | OLEMA PHARMACEUTICALS INC | $65.6M | 3.29% | 4.4M | Added |
| 13 | BBIO | BRIDGEBIO PHARMA INC | $63.1M | 3.17% | 850,000 | Trimmed |
| 14 | BIOA | BIOAGE LABS INC | $50.6M | 2.54% | 2.9M | Added |
| 15 | CNTA | CENTESSA PHARMACEUTICALS PLC | $41.7M | 2.09% | 1.1M | Trimmed |
| 16 | GLTO | DAMORA THERAPEUTICS INC | $39.5M | 1.98% | 1.5M | New |
| 17 | MBX | MBX BIOSCIENCES INC | $33.4M | 1.68% | 1.1M | Hold |
| 18 | INSM | INSMED INC | $31.1M | 1.56% | 190,000 | Trimmed |
| 19 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $30.4M | 1.53% | 950,000 | Trimmed |
| 20 | TNGX | TANGO THERAPEUTICS INC | $29.8M | 1.50% | 1.4M | New |
| 21 | PHVS | PHARVARIS N V | $28.2M | 1.42% | 1.0M | Trimmed |
| 22 | ORKA | ORUKA THERAPEUTICS INC | $26.2M | 1.31% | 533,340 | Hold |
| 23 | AGOMAB THERAPEUTICS NV | $25.9M | 1.30% | 2.5M | New | |
| 24 | MAZE | MAZE THERAPEUTICS INC | $22.4M | 1.12% | 750,000 | New |
| 25 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $22.0M | 1.11% | 2.3M | Hold |
Source: SEC Form 13F filings · as of 2026-03-31